Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.06 - A Novel EGFR G724S and R776H Rare Co-Mutation Response to Afatinib in a Patient With Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Dong Shen
- Abstract
Loading... -
+
P76.21 - EGFR-KDD with Duplication of Exons 18-26 Responding to Afatinib Treatment in a Patient with Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Yiying Qian
- Abstract
Loading... -
+
P76.38 - Afatinib as a Potential Therapeutic Option for Non-small Cell Lung Cancer Patients with EGFR G724S
00:00 - 00:00 | Presenter: Hongyun Zhao
- Abstract
Loading... -
+
P76.55 - Real-world Experience of the Utility in Afatinib Therapy for Patients with EGFR-Mutant Advanced NSCLC
00:00 - 00:00 | Presenter: Satoshi Igawa
- Abstract
Loading... -
+
P76.70 - Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Jacqueline V. Aredo
- Abstract
Loading... -
+
P76.83 - Brain Metastasis from Lung Cancers - Intermittent High Dose Afatinib as a Palliative Salvage Therapy for EGFR+ NSCLC.
00:00 - 00:00 | Presenter: Jo Monsen
- Abstract
Loading... -
+
P76.85 - Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors
00:00 - 00:00 | Presenter: Sukhmani K. Padda
- Abstract
Loading... -
+
P76.96 - START: Real-world Prospective Study on Sequential Therapy with First-Line Afatinib in Chinese Patients with EGFRm+ Advanced NSCLC
00:00 - 00:00 | Presenter: Jianying Zhou
- Abstract
Loading... -
+
P76.99 - Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
00:00 - 00:00 | Presenter: Dongqing Lv
- Abstract
Loading...
